Progress of treatment for primary mediastinal B-cell lymphoma
10.3760/cma.j.issn.1673-422X.2019.08.013
- VernacularTitle:原发性纵隔B细胞淋巴瘤治疗的研究进展
- Author:
Mingyue XIANG
1
;
Lili WANG
;
Dali HAN
Author Information
1. 山东省肿瘤防治研究院(山东省肿瘤医院)放疗科
- Keywords:
Lymphoma,B-cell;
Radiotherapy;
Rituximab;
Chemotherapy
- From:
Journal of International Oncology
2019;46(8):505-508
- CountryChina
- Language:Chinese
-
Abstract:
Primary mediastinal B-cell lymphoma (PMBCL) is aggressive B-cell lymphoma with unique clinicopathologic characteristics.However,under the new classification of PMBCL,whether R-CHOP was the standard first-line immunotherapy regimen remains a controversy.The DA-EPOCH-R is not inferior to R-CHOP,but attention should be paid to the toxic effects.PMBCL is a radiosensitive disease,but radiotherapy did not as the front-line therapy for PMBCL.A biopsy is required for positive PET/CT after immunotherapychemotherapy to determine the further treatment of PMBCL.Recurrent/refractory PMBCL,with poor prognosis,salvage immunochemotherapy is often used followed by high-dose chemotherapy and autologous stem cell transplant.PD-1 overexpression is common in recurrent/refractory PMBCL,and immune checkpoint inhibitors are potential to be an important treatment option.Recently,the development of molecular medicine has provided a new basis for the selection of targets in PMBCL,however,it needs to be further confirmed by clinical trials.
